Dyadic International, Inc. (OTCQX: DYAI)  is a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Biotechnology

Dyadic International

Mark A. Emalfarb

Joseph Hazelton

Teams at Dyadic International

Business Development and Licensing

Leadership Team

Finance and Accounting